Tags

Type your tag names separated by a space and hit enter

Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey.
J Am Geriatr Soc. 2009 Dec; 57(12):2269-74.JA

Abstract

OBJECTIVES

To determine the frequency of cholinesterase inhibitor (ChEI) use in nursing home (NH) residents with dementia and examine correlates of ChEI use in this population.

DESIGN

Cross-sectional study using the 2004 National Nursing Home Survey (NNHS).

SETTING

A representative, stratified, random sample of U.S. NHs.

PARTICIPANTS

All NNHS participants aged 65 and older with a chart diagnosis of dementia.

MEASUREMENTS

Bivariate analyses to compare characteristics of NH residents with dementia according to ChEIs status and multivariable logistic regression to identify independent correlates of ChEI use.

RESULTS

Almost half (49.1%) of NNHS participants had dementia, and 30.0% of those with dementia were receiving ChEIs. Donepezil accounted for 71% of all ChEI prescriptions. Multivariable logistic regression showed that ChEI use was independently associated with younger age (odds ratio (OR)=0.42, 95% confidence interval (CI)=0.28-0.64, aged > or =95 vs 65-74), less activity of daily living impairment (OR=0.49, 95% CI=0.42-0.58, severe vs mild impairment), greater use of antipsychotics (OR=1.33, 95% CI=1.16-1.54) and antidepressants (OR=1.38, 95% CI=1.20-1.59), and residence in NHs with more beds (OR=1.52, 95% CI=1.07-2.16, > or =200 beds vs <50 beds).

CONCLUSION

Approximately 30% of NH residents with dementia in U.S. NHs are treated with ChEIs. Functional impairment and medical comorbidity are common in ChEIs users, although users tend to be younger and less impaired than NH residents with dementia who are not receiving ChEIs. Further study is required to determine the optimum use of ChEI in NH populations.

Authors+Show Affiliations

Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada. dallas_seitz@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19874411

Citation

Seitz, Dallas P., et al. "Cholinesterase Inhibitor Use in U.S. Nursing Homes: Results From the National Nursing Home Survey." Journal of the American Geriatrics Society, vol. 57, no. 12, 2009, pp. 2269-74.
Seitz DP, Gruneir A, Conn DK, et al. Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey. J Am Geriatr Soc. 2009;57(12):2269-74.
Seitz, D. P., Gruneir, A., Conn, D. K., & Rochon, P. A. (2009). Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey. Journal of the American Geriatrics Society, 57(12), 2269-74. https://doi.org/10.1111/j.1532-5415.2009.02552.x
Seitz DP, et al. Cholinesterase Inhibitor Use in U.S. Nursing Homes: Results From the National Nursing Home Survey. J Am Geriatr Soc. 2009;57(12):2269-74. PubMed PMID: 19874411.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cholinesterase inhibitor use in U.S. nursing homes: results from the national nursing home survey. AU - Seitz,Dallas P, AU - Gruneir,Andrea, AU - Conn,David K, AU - Rochon,Paula A, Y1 - 2009/10/26/ PY - 2009/10/31/entrez PY - 2009/10/31/pubmed PY - 2010/3/4/medline SP - 2269 EP - 74 JF - Journal of the American Geriatrics Society JO - J Am Geriatr Soc VL - 57 IS - 12 N2 - OBJECTIVES: To determine the frequency of cholinesterase inhibitor (ChEI) use in nursing home (NH) residents with dementia and examine correlates of ChEI use in this population. DESIGN: Cross-sectional study using the 2004 National Nursing Home Survey (NNHS). SETTING: A representative, stratified, random sample of U.S. NHs. PARTICIPANTS: All NNHS participants aged 65 and older with a chart diagnosis of dementia. MEASUREMENTS: Bivariate analyses to compare characteristics of NH residents with dementia according to ChEIs status and multivariable logistic regression to identify independent correlates of ChEI use. RESULTS: Almost half (49.1%) of NNHS participants had dementia, and 30.0% of those with dementia were receiving ChEIs. Donepezil accounted for 71% of all ChEI prescriptions. Multivariable logistic regression showed that ChEI use was independently associated with younger age (odds ratio (OR)=0.42, 95% confidence interval (CI)=0.28-0.64, aged > or =95 vs 65-74), less activity of daily living impairment (OR=0.49, 95% CI=0.42-0.58, severe vs mild impairment), greater use of antipsychotics (OR=1.33, 95% CI=1.16-1.54) and antidepressants (OR=1.38, 95% CI=1.20-1.59), and residence in NHs with more beds (OR=1.52, 95% CI=1.07-2.16, > or =200 beds vs <50 beds). CONCLUSION: Approximately 30% of NH residents with dementia in U.S. NHs are treated with ChEIs. Functional impairment and medical comorbidity are common in ChEIs users, although users tend to be younger and less impaired than NH residents with dementia who are not receiving ChEIs. Further study is required to determine the optimum use of ChEI in NH populations. SN - 1532-5415 UR - https://www.unboundmedicine.com/medline/citation/19874411/Cholinesterase_inhibitor_use_in_U_S__nursing_homes:_results_from_the_national_nursing_home_survey_ L2 - https://doi.org/10.1111/j.1532-5415.2009.02552.x DB - PRIME DP - Unbound Medicine ER -